Meta-analysis evaluates cannabidiol efficacy for seizure freedom rates in refractory epilepsy syndromes, indicating potential treatment benefits.
To evaluate the efficacy of cannabidiol (CBD) in achieving seizure freedom (SF) and ≥50% responder rates (RR50) in patients with Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and Tuberous Sclerosis Complex (TS).
No takes yet. Share an insight, caveat, or question.
Elmandouh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: